{"pub": "foxnews", "url": "https://foxbusiness.com/healthcare/how-will-purdue-pharmas-bankruptcy-affect-pending-litigation", "downloaded_at": "2019-09-16 23:11:21.567875+00:00", "title": "How will Purdue Pharma's bankruptcy affect pending litigation?", "language": "en", "text": "Purdue Pharma\u2019s recent bankruptcy filing will effectively halt more than 2,000 lawsuits filed against the company, and could mark the beginning of a \u201cpotentially endless process,\u201d experts told FOX Business.\n\nContinue Reading Below\n\nArguably most known for making billions in the sale of the highly addictive prescription opioid OxyContin, Purdue Pharma filed for Chapter 11 bankruptcy in White Plains, New York on Sunday.\n\nThe filing was part of a tentative settlement between the pharmaceutical company and dozens of state and federal agencies that have filed suit against them.\n\nIn a statement released after the bankruptcy was announced, Steve Miller, the chairman of Purdue\u2019s board of directors, said: \u201cThis unique framework for a comprehensive resolution will dedicate all of the assets and resources of Purdue for the benefit of the American public.\u201d\n\nBut what happens to the more than 2,000 lawsuits that are still pending against the Stamford, Connecticut-based company, and what does this mean for the first-of-its-kind federal trial scheduled to begin next month, for which Purdue Pharma was named as a defendant?\n\nAdvertisement\n\n\u201cThe Oct. 21 trial in Cleveland, Ohio, will have to go forward without them,\u201d said New York-based lawyer Paul Hanly, who is one of three lead attorneys on the federal litigation.\n\nThe remaining drug companies \u2013 a mix of opioid retailers, distributors and manufacturers, among others \u2013 \u201cought to be preparing for trial because we feel confident that the trial to go forward,\u201d Hanly told FOX Business.\n\n\u201cOne of the main claims in the Cleveland trial is that the defendants created and then perpetuated a public nuisance \u2013 in other words, they created a circumstance where the public at large has been harmed from the opioid epidemic.\u201d\n\nThe other key issue, Hanly said, is whether the companies committed acts of racketeering while doing business.\n\nAlthough the trial in Cleveland will likely be going forward without Purdue, \u201cwe will be working hard in the bankruptcy proceedings to try to get some sort of a deal for Purdue and [billionaire founding family] the Sacklers,\u201d Hanly said.\n\n\u201cIt is a potentially endless process and some of these bankruptcies \u2013 I think Purdue possibly could fall under this category \u2013 are so complex that they take more than a decade to finish,\u201d Hanley said. \u201cAt the end of which, the debtor, Purdue\u2019s cash, is all spent.\u201d\n\nHanly noted that communities nationwide \u201care suffering so badly, a deal in bankruptcy where perhaps the funds could start to flow out in a year is far better.\u201d\n\nFor the time being, however, any and all litigation \u2013 likely barring, in this case, October\u2019s federal trial \u2013 has been effectively brought to a halt.\n\n\u201cFor this company, any of the lawsuits now are on hold,\u201d bankruptcy attorney Jenee Ciccarelli explained. \u201cWhat will then happen is that the plaintiffs in those suits will have to go to the bankruptcy court and apply for relief from the automatic stay to pursue the case in the court that they\u2019re in.\u201d\n\nFor those companies that have already been granted settlements, the designated funds will be added to the bankruptcy filing to be part of the fund reorganization process, she explained.\n\nCLICK HERE TO READ MORE ON FOX BUSINESS\n\nCiccarelli, who is based in New York, called the bankruptcy filing \u201ca real smart move.\u201d\n\nStill, \u201cthis is, in fact, a nationwide epidemic,\u201d she said, noting: \u201cIt won\u2019t save them from any future suits after bankruptcy is over, but for now, it absolutely protects them.\u201d", "description": "What happens to the more than 2,000 lawsuits that are still pending against the company, and what does this mean for the federal trial scheduled to begin next month?", "authors": ["Stephanie Pagones"], "top_image": "https://a57.foxnews.com/static.foxbusiness.com/foxbusiness.com/content/uploads/2019/09/0/0/oxycontin-AP.jpg?ve=1&tl=1", "published_at": "2019-09-16"}